Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14.
No abstract available

Keywords: bendamustine; elderly; multiple myeloma; relapse.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Dexamethasone / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Nitrogen Mustard Compounds / administration & dosage
  • Prognosis
  • Pyrazines / administration & dosage
  • Survival Rate

Substances

  • Boronic Acids
  • Nitrogen Mustard Compounds
  • Pyrazines
  • Bortezomib
  • Dexamethasone
  • Bendamustine Hydrochloride

Associated data

  • ClinicalTrials.gov/NCT01045681